Key terms

About TARA

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest TARA news

May 06 6:18am ET Buy Rating Affirmed for Protara Therapeutics Amid Promising Clinical Trials and Market Potential for TARA-002 by TipRanks May 02 4:18pm ET Protara Therapeutics files to sell 21.69M shares of common stock for holders by TipRanks May 02 8:03am ET Protara Therapeutics reports Q1 EPS (97c), consensus (92c) by TipRanks Apr 22 7:25am ET Protara Therapeutics (TARA) Receives a Buy from Oppenheimer by TipRanks Apr 22 7:23am ET Protara Therapeutics price target raised to $30 from $26 at Oppenheimer by TipRanks Apr 08 6:15am ET Buy Rating for Protara Therapeutics’ TARA-002 Based on Promising Clinical Data and Market Potential in NMIBC Treatment by TipRanks Apr 05 8:32am ET Protara Therapeutics Launches $45M Private Placement Drive by TipRanks Apr 05 8:19am ET Protara Therapeutics announces $45M private placement financing by TipRanks Apr 05 8:14am ET Protara Therapeutics announces three-month data from TARA-002 program by TipRanks Apr 05 8:05am ET Protara announces alignment with FDA on path forward for IV Choline Chloride by TipRanks Mar 18 5:32pm ET Protara Therapeutics CMO Resigns, Interim Successor Named by TipRanks Mar 14 6:30am ET Analysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB) by TipRanks Mar 13 12:05pm ET Buy Rating on Protara Therapeutics Backed by Promising TARA-002 Clinical Trials and Significant Market Opportunity by TipRanks Mar 13 8:02am ET Protara Therapeutics expects cash to fud operations into 2Q25 by TipRanks Mar 13 8:02am ET Protara Therapeutics reports Q4 EPS (90c), consensus (92c) by TipRanks

No recent press releases are available for TARA

TARA Financials

1-year income & revenue

Key terms

TARA Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

TARA Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Scaffolding and construction netting near an apartment building in New York, US, on Wednesday, Oct. 11, 2023. Monthly fees and expenses for inspections, insurance and climate-friendly upgrades are squeezing residents of the city's many co-op and condo buildings. Photographer: Michael Nagle/Bloomberg
Michael Nagle/Bloomberg/Getty Images
For US renters, the chance of owning a home is going from bad to worse
Close-up detail of the Disney+ app icon on an Apple iPhone 12 Pro smartphone screen, on November 11, 2020. (Photo by Phil Barker/Future Publishing via Getty Images)
Phil Barker/Future Publishing/Getty Images
Disney just had its worst day in a year and a half
People shop in a supermarket in the Manhattan borough of New York city on January 27, 2024. (Photo by Charly TRIBALLEAU / AFP) (Photo by CHARLY TRIBALLEAU/AFP via Getty Images)
Charly Triballeau/AFP/Getty Images
Americans have spent their savings. Economists worry about what comes next
Berkshire Hathaway Chairman Warren Buffett walks through the exhibit hall as shareholders gather to hear from the billionaire investor at Berkshire Hathaway Inc's annual shareholder meeting in Omaha, Nebraska, on May 4, 2019.
Scott Morgan/Reuters/File
Warren Buffett compares AI to nuclear weapons in stark warning